

ABSTRACT OF THE DISCLOSURE

5 A pharmaceutical composition is provided for
treatment and/or prevention of a disease, a disorder and/or
a condition caused by expression of a gene controlled by
NF-KB or ets. The composition comprises at least one decoy
and a pharmaceutically acceptable carrier. The decoy is an
NF-KB decoy, an ets decoy, or a chimera decoy of NF-KB and
ets. The disease is cerebral aneurysm, cancer, Marfan's
10 syndrome, aortic detachment, post-angioplasty restenosis,
chronic articular rheumatism, asthma, atopic dermatitis,
nephritis, renal failure, or plaque rupture. Alternatively,
the disease is a disease associated with eosinophilic
abnormality (e.g., asthma, vascular diseases, allergic
15 diseases, parasite diseases). The pharmaceutically
acceptable carrier may be a hydrophilic polymer, a liposome,
or the like.